Abstract:Background Circulating levels of soluble suppression of tumorigenicity-2 (sST2) reflect vascular congestion, inflammation, and fibrosis. sST2 has been proposed as a useful biomarker to predict the mortality and hospitalization due to heart failure. However, there is limited evidence regarding the relationship between sST2 and heart failure, as well as other comorbidities, in severe coronary heart disease (CAD). Purpose This study aims to measure the circulating levels of soluble ST2 (sST2) in a large population of patients with severe CAD to determine its association with heart failure, cardiac function, inflammation, and other important comorbidities. Methods This subanalysis is part of the ongoing perspective observational study. Available serum samples from 520 patients undergoing elective coronary artery bypass grafting (CABG) were analysed for sST2 levels. The inclusion criteria were written informed consent and age between 18-85 years. Exclusion criteria for this analysis were severe valvular disease, severe chronic obstructive pulmonary disease, oxygen therapy, nocturnal positive airway pressure support or mechanical ventilation, and the need for catecholamines or circulatory assist devices. The circulating levels of human sST2 were measured from frozen serum (-80°C) using commercially available ELISA kits. The plasma was diluted 100 times to detect sST2 levels (assay range of 31.2 - 2,000 pg/mL). Two measurements were taken to account as means for intra-assay variabilities. Logarithmic transformation was used to convert non-normal distributed data. Student t' test and linear regression were applied to categorical or continuous variables as appropriate. Results sST2 levels (median 20.4 ng/ml, [IQR 15.5 – 28.8]) significantly predict worse left ventricular ejection fraction (β = -0.164, p = 0.006), and significantly correlate with levels of NT-proBNP (β = 3.263, p < 0.001), hs-Troponin T (β = 3.391, p < 0.001), high-sensitivity C-reactive protein (β = 2.472, p = 0.014) and heart failure (p= 0.002). Interestingly, common comorbidities such as chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2, p = 0.004), diabetes mellitus (p = 0.001) and higher levels of glycated haemoglobin (HbA1c, β = 3.615, p < 0.001) showed also a significant association with sST2 levels. No significant association of sST2 was observed with arterial hypertension (p = 0.190), atrial fibrillation (p = 0.289), obesity (BMI ≥ 30 kg/m2, p = 0.302), sleep apnoea (apnoea-hypopnoea index ≥ 15/h, p = 0.068), peripheral artery disease (p = 0.823), or previous stroke (p = 0.861). Conclusion(s) Circulating levels of sST2 significantly correlate with heart failure, NT-proBNP, hs-TnT, and hs-CRP in patients with severe CAD. Additionally, sST2 levels were found to be elevated in patients with diabetes mellitus and chronic kidney disease.

Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

The Biological Characteristics and Clinical Significance of a Novel Heart Failure Marker：sst2

Correlation of Plasma Soluble Suppression of Tumorigenicity-2 Level with the Severity and Stability of Coronary Atherosclerosis

Clinical application and research progresses of soluble growth stimulation expressed gene 2 protein in coronary artery disease and heart failure

Soluble ST2 as a possible biomarker for inflammation in patients with acute heart failure

Elevated Serum Levels of Soluble ST2 Are Associated with Plaque Vulnerability in Patients with Non-ST-Elevation Acute Coronary Syndrome

Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and <i>meta</i>-analysis

Association of soluble ST2 with heart failure and other comorbidities in patients with severe coronary heart disease

ST2 and prognosis in acute heart failure

Soluble ST2 Is a Biomarker Associated With Left Ventricular Hypertrophy and Concentric Hypertrophy in Patients With Essential Hypertension

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis

Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure

Soluble ST2 in Patients with Carotid Artery Stenosis—Association with Plaque Morphology and Long-Term Outcome

Association Between Level of Plasma Soluble ST2 and Degrees of Coronary Artery Stenosis in Acute Myocardical Infarction

A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT)

Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure

Prognostic Value of Sst2 in Patients with Heart Failure with Reduced, Mid-Range and Preserved Ejection Fraction.

The Relationship Between the Serum Level of Soluble ST2 and the Severity and Prognosis of Heart Failure

ST2 Silencing Aggravates Ventricular Remodeling and Chronic Heart Failure in Rats by Mediating the IL-33/ST2 Axis